Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

Neuren and Metabolic collaborate to develop range of nerve repair compounds

Neuren Pharmaceuticals Ltd (Neuren) and Metabolic Pharmaceuticals Ltd (Metabolic) have announced that the two companies have agreed to collaborate to co-develop Neuren's class of Neuro-regenerative Peptides (NRPs) for the treatment of degenerative conditions such as peripheral neuropathy, motor neuron disease and repairing the brain or nerves after injuries such as spinal cord injury.

7 Mar 2005

Marijuana-like compounds may aid Parkinson's disease, pain and obesity

No longer a pipe dream, new animal research now indicates that marijuana-like compounds can aid a bevy of debilitating conditions, ranging from brain disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease, to pain and obesity.

28 Oct 2004

Cymbalta significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression

The antidepressant Cymbalta (duloxetine HCl), a dual-reuptake inhibitor of serotonin and norepinephrine, 60 mg once or twice daily, significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression, according to 12-week data presented at the annual meeting of the American College of Rheumatology.

18 Oct 2004

European positive for Cymbalta and Xeristar

Eli Lilly and Company and Boehringer Ingelheim have announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.

20 Sep 2004

Botox injections may ease the irritation of tinnitus

A preliminary study indicates that Botox injections may ease the irritation of tinnitus, otherwise know as ringing in the ears, for some patients. Researchers say more study is needed, but initial results are promising.

18 Sep 2004

Cymbalta, treatment for major depression hits the market

Cymbalta, a new treatment for major depression, is now available by prescription in pharmacies across the United States, Eli Lilly and Company has announced.

26 Aug 2004

Cymbalta, a new treatment for major depression

Cymbalta, a new treatment for major depression, is now available by prescription in pharmacies across the United States, Eli Lilly and Company have announced.

25 Aug 2004

Sea snail offers natural healing powers for a range of illnesses from chronic pain to diseases of the brain

A beautiful, but often deadly, snail from the sea has been revealed as a largely untapped source of natural healing powers for a range of illnesses from chronic pain to diseases of the brain.

20 Aug 2004

New biotech alliance to focus on diseases of nerve injury and pain

NeuroTargets Ltd, a discovery-led biotechnology company ‘spun-out’ from the University of Bristol, has formed an exciting new alliance with BioFocus plc, a world leader in collaborative drug discovery, to focus on diseases of nerve injury and pain.

11 Aug 2004

Approval of Cymbalta for treatment of major depressive disorder

The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl; pronounced SIM-BALL-TA), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company have announced.

5 Aug 2004

Cannabis extract drug may help patients with rheumatoid arthritis

The multi centre double blind, randomised, parallel group study in 58 patients assessed the efficacy, safety and tolerability of Sativex®, a whole plant medicinal cannabis extract, compared with placebo for the treatment of pain caused by Rheumatoid Arthritis. Study medication was administered by means of a spray into the mouth as an evening dose only and measures were assessed the following day.

11 Jun 2004

A new synthetic chemical may provide framework for future drugs to treat brain-based ailments

A new synthetic chemical may provide the framework for future drugs that can treat a variety of brain-based ailments, ranging from overeating and drug dependency to neuropathic pain.

19 May 2004

New Canadian drug submission for cannabis-based medicine

GW Pharmaceuticals and Bayer HealthCare, Pharmaceuticals Division - Canada have announced that GW has submitted a New Drug Submission for Sativex®, a cannabis-based medicinal extract product, to Health Canada.

13 May 2004

Studies show pregabalin does not affect male reproductivity or interfere with oral contraceptives

Two studies presented today at the American Academy of Neurology (AAN) 56th Annual Meeting show that pregabalin, when used as an add-on treatment for epilepsy, does not affect male reproductive function or interfere with the effectiveness of oral contraceptives.

29 Apr 2004